Track record · closed signal

MannKind Corporation (MNKD) — closed signal from September 28, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 27, 2025.

Predicted vs. what happened

MNKD price · publication thesis → realized outcomesplit-adjusted
$5.53 Published $7.74 Target $5.79 Window close $6.24 Peak
$5.20 – $5.60Entry zone — fair-value band
$5.53Published — price the day we called it
$7.74Target — the price the thesis aimed for
$6.24Peak — highest point inside the window, not a realized return
$5.79Window close — end-of-window price, context only

What happened

Partial

Reached 32% of the predicted growth at its peak, without hitting the target.

Peak price
$6.24
peak on November 5, 2025 — not a realized return
Peak gain
+12.8%
peak, from the publication price
Window close
$5.79
end-of-window price, context only
Days to target
—
Window
September 28, 2025 – December 27, 2025

The thesis — published September 28, 2025

Predicted growth
+40%
over the measurement window
Target price
$7.74
the price the thesis aimed for
Entry zone
$5.20 – $5.60
the fair-value band we waited for
Price at publication
$5.53
published September 28, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

- Explain the company story and why it could grow - Translate complex terms into plain language - Note what to watch over the next 3 months MannKind expanded its work with United Therapeutics, adding $5M and third-party confidence. Investor mood is strong, with lots more people buying than usual. The recent average price is rising, so dips look buyable. If healthcare interest stays firm, a move toward the prior price ceiling in about 3 months looks possible.

Primary drivers

  • Bigger deal with United Therapeutics adds cash and shows real-world trust
  • Investor mood is very positive, with far more buying than a normal day
  • Recent average price is rising, while another momentum sign is trailing
  • More money is moving into biotech after recent rate cut, aiding demand

How it played out

MNKD: thesis rose but missed the target

Lyra published MNKD at $5.53 on 2025-09-28 with a short-term view for 40% growth. The thesis pointed to a bigger United Therapeutics deal, $5M of added cash, very positive investor mood, a rising recent average price, and more money moving into biotech after a recent rate cut.

Inside the window from 2025-09-28 to 2025-12-27, MNKD peaked at $6.24 on 2025-11-05, a 12.8% gain. It stayed below the $7.74 target and never reached it. The stock ended at $5.79. The thesis partly played out, but the target missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MNKD signals